Drug intelligence / Profile preview

AIM Hanxin

Development stage: Unknown
Lead developer: AIM Vaccine Co.
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AIM Hanxin is a recombinant protein vaccine developed by AIM Honesty for the prevention of hepatitis B virus (HBV) infection. The vaccine utilizes the *Hansenula polymorpha* yeast expression system to produce the hepatitis B surface antigen (HBsAg), which serves as the active ingredient. Upon administration, the vaccine induces protective neutralizing antibodies (anti-HBs) and cellular immune responses against the virus. It is approved in China for various populations, including infants, children, and adults. Clinical data has demonstrated a high blocking rate (97.36%) for mother-to-child transmission in infants born to HBsAg-positive and HBeAg-positive mothers, with an average antibody positive rate of 99%. The vaccine was included in the Chinese Pharmacopoeia in 2010 and holds a significant market share in the Chinese domestic market.

Brand names: AIM HanxinHan Xun Rui An
Other names: Recombinant Hepatitis B Vaccine (Hansenula Polymorpha)Recombinant Hepatitis B Vaccine

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on AIM Hanxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIM Hanxin.

Explore the full profile